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Introduction: Psoriasis vulgaris is a common inflammatory disease of the skin, and myelin-associated glycoprotein-
related neuropathy is a chronic sensory-predominant polyneuropathy. Although both of these diseases are
considered autoimmune diseases, psoriasis with concomitant myelin-associated glycoprotein-related neuropathy is
very rare. Here, we report a case of myelin-associated glycoprotein-related neuropathy associated with psoriasis.
Case presentation: A 66-year-old Japanese man, having experienced sternocostoclavicular pain for ten years, was
admitted to our hospital because of gait disturbance and numbness of the limbs. Our patient had normal cranial
nerve function and normal limb muscle strength. His vibratory and position sense was severely impaired and his
touch, temperature and pinprick sensations were mildly disturbed in a glove and stocking distribution. A
myelin-associated glycoprotein western blot analysis showed the presence of a 91 to 94kDa band using purified
human myelin-associated glycoprotein antigen. His skin lesions were moderately pruritic and Auspitz’s sign was
positive. Our patient also showed osteitis of his clavicle and manubrium. We diagnosed our patient with
myelin-associated glycoprotein-related neuropathy associated with psoriatic arthritis. Five days after intravenous
immunoglobulin therapy, his deep sensory impairment began to improve and his sternocostoclavicular pain
diminished dramatically.
Conclusions: Because myelin-associated glycoprotein-related neuropathy and psoriatic arthritis are both considered
autoimmune diseases, we conclude that intravenous immunoglobulin therapy is very effective for patients with an
association of these diseases.Introduction
Psoriasis vulgaris is a common inflammatory disease of the
skin characterized by erythematous, dry, scaling plaques of
various sizes [1]. Myelin-associated glycoprotein (MAG)-
related neuropathy is a chronic sensory-predominant poly-
neuropathy with less than severe motor involvement.
Although both of these diseases are considered auto-
immune diseases, psoriasis with concomitant MAG-related
neuropathy is very rare.
Case presentation
A 66-year-old Japanese man, having experienced sterno-
costoclavicular pain for 10 years, was admitted to our hos-
pital because of gait disturbance and numbness of the* Correspondence: kemurata@wakayama-med.ac.jp
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reproduction in any medium, provided the orlimbs. A physical examination revealed no abnormalities
except for skin eruptions on the bilateral elbows, knees
and hips (Figure 1). The diameter of each plaque was ap-
proximately 2cm to 5cm. These eruptions developed two
years before admission and appeared as erythematous pla-
ques covered by a silvery scaling. The skin lesions were
moderately pruritic and Auspitz’s sign was positive. These
findings are compatible with psoriasis vulgaris.
On neurological examination, our patient had normal
cranial nerve function and normal limb muscle strength.
All deep tendon reflexes were absent. His vibratory and
position sense was severely impaired up to his knees.
Touch, temperature and pinprick sensations were mildly
disturbed in a glove and stocking distribution. His co-
ordination was clumsy in his lower limbs because of sen-
sory ataxia. He had gait disturbance with Romberg’s sign.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Psoriatic lesion on the knee.
Figure 2 Light micrograph of a sural nerve biopsy and a bone
scintigram. Light micrograph of a sural nerve biopsy showing a
moderate reduction in the density of large myelinated fibers, with
(A) abnormally thin myelin relative to axonal caliber (arrows) in a
cross section (bar=30μm) and (B) teased fibers with short, thinly
myelinated internodes (arrows), indicating remyelination (bar=100μm).
(C) A bone scintigram showing an abnormal accumulation of 99mTc in
both of the sternocostoclavicular joints and the right clavicular region.
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concentration of immunoglobulin (Ig) M was 320mg/dL
(normal range: 51 to 260mg/dL), but other immunoglobu-
lins were within the normal range. Serum immunoelectro-
phoresis showed IgM K-type monoclonal gammopathy. An
enzyme-linked immunosorbent assay confirmed that the
serum obtained from our patient before treatment con-
tained extremely high titers of IgM antibody against MAG
and sulfated glucuronyl paragloboside. A MAG western
blot analysis showed the presence of a 91 to 94kDa band
using purified human MAG antigen. No tumor cell prolif-
eration was observed in a bone marrow aspiration study.
Autoantibodies, including anti-deoxyribonucleic acid
(DNA), anti-SS-A and anti-SS-B were not detected. Assays
for ganglioside antibodies against GM1, GM2, GM3,
GD1a, GD1b, GD3, GT1b, GQ1b, GA1 and Gal-C were
negative. The titer of cold agglutinin was not increased.
There was no cerebral spinal fluid pleocytosis, but his cere-
bral spinal fluid protein level was 300mg/dL.
Motor conduction studies showed a reduced velocity in
his ulnar nerve (30m/s; normal range, >50m/s) and no
compound muscle action potential from his extensor digi-
torum brevis muscle after peroneal nerve stimulation.
Sensory nerve action potentials could not be detected in
either upper or lower limbs. A sural nerve biopsy showed
a moderate reduction in density of large myelinated fibers
(Figure 2A), with remyelinated fibers comprising 21.8% of
all teased fibers (Figure 2B). His sternocostoclavicular
joints and right clavicular region showed active uptake of
the radioisotope 99mTc, consistent with osteitis of the clav-
icle and manubrium (Figure 2C).
Our patient was human leukocyte antigen B39 positive,
but negative for B27. We diagnosed our patient with
MAG-related neuropathy associated with psoriatic arth-
ritis. Intravenous immunoglobulin (IVIg) therapy, 400mg/kg/day for five days, was administered. His deep sensory
impairment began to improve five days after starting IVIg
therapy. The severity of his sensory ataxia was evaluated
by the size of the estimated area when our patient stood
on a stabilometer with closed stance under open eye or
closed eye conditions. The estimated areas under open
eye conditions showed no remarkable changes after IVIg
treatment (pretreatment area, 10.0cm2; post-treatment
area, 10.5cm2). However, estimated areas under closed eye
conditions became smaller after IVIg treatment (pretreat-
ment area, 56.2cm2; post-treatment area, 37.4cm2). One
week later, our patient observed that his sternocostoclavi-
cular pain was dramatically diminished and his inflamma-
tory markers improved (erythrocyte sedimentation rate
decreased from 66 to 20mm in the first hour and C-
reactive protein decreased from 3.63 to 1.28mg/dL). The
improvement of his sensory ataxia persisted for at least
three months.
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Our patient had psoriasis and MAG-related neuropathy
at the same time. The selection of an effective immuno-
suppressive therapy for both diseases is very difficult, be-
cause MAG-related neuropathy is related to B cell
immunity, whereas psoriasis is considered an auto-
immune disease with T cells playing a key role in the
pathogenesis [1]. Indeed, IVIg therapy is effective for
patients with chronic inflammatory demyelinating poly-
neuropathy, but it is not a standard therapy for a patient
with MAG-related neuropathy. The small clinical trials
that have been reported show no convincing effect, other
than short term [2]. Although the combined administra-
tion of IVIg and interferon-β-1a is effective in patients
with acute inflammatory demyelinating polyneuropathy
[3], it is not obvious that this combined therapy is effect-
ive in patients with MAG-related neuropathy.
Several therapies have been proposed for psoriasis,
including topical corticosteroid, vitamin D analogues,
phototherapy and systemic immunosuppressants. Tumor
necrosis factor alpha (TNF-α) is an important immuno-
modulator that plays a role in immune system develop-
ment, immune response regulation and T-cell-mediated
tissue injury [4]. Recently, TNF-α blockers were sug-
gested for the treatment of inflammatory disorders in-
cluding rheumatoid arthritis, psoriasis and psoriatic
arthritis [5]. However, they can induce autoimmunity
and have induced peripheral nerve demyelinating dis-
eases such as chronic inflammatory demyelinating poly-
neuropathy [6]. Although there was no significant
improvement in the cutaneous lesions of psoriasis, IVIg
therapy is known to be effective for psoriasis or psoriatic
arthritis [7,8]. Therefore, we chose IVIg therapy because
the symptoms of MAG-related neuropathy may be exa-
cerbated by anti-TNF-α therapy. Fortunately, IVIg ther-
apy dramatically improved not only the sensory ataxia
but also the sternocostoclavicular pain.
There are a few publications that describe patients
with psoriasis who develop polyneuropathy, and most of
these patients showed axonopathy [9-11]. Demyelinating
neuropathy associated with psoriasis is very rare, and
MAG-related neuropathy is classified as a demyelinating
neuropathy [2]. Thus, concomitant occurrence of psoria-
sis and MAG-related neuropathy may be by chance.
Psoriasis is easy to observe, but MAG-related neur-
opathy is not. Therefore, close attention should be paid
to the coexistence of MAG-related neuropathy with
psoriasis to avoid side effects of immune therapy, espe-
cially anti-TNF-α therapy.
Conclusion
We conclude that IVIg therapy is very effective for
patients with MAG-related neuropathy associated with
psoriatic arthritis.Consent
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